Modality
Radioligand
MOA
Cl18.2
Target
Aβ
Pathway
RAS/MAPK
Bladder Ca
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
Jul 2018
→ Nov 2030
Phase 1Current
NCT07804375
1,714 pts·Bladder Ca
2018-07→2030-11·Completed
NCT05436439
1,364 pts·Bladder Ca
2024-01→2027-05·Completed
3,078 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-05-201.1y awayPh2 Data· Bladder Ca
2030-11-154.6y awayPh2 Data· Bladder Ca
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1/2
Complet…
P1/2
Complet…
Catalysts
Ph2 Data
2027-05-20 · 1.1y away
Bladder Ca
Ph2 Data
2030-11-15 · 4.6y away
Bladder Ca
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07804375 | Phase 1/2 | Bladder Ca | Completed | 1714 | BodyWt |
| NCT05436439 | Phase 1/2 | Bladder Ca | Completed | 1364 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| VRT-5853 | Vertex Pharma | Phase 3 | Aβ | |
| ARG-314 | Argenx | Approved | Aβ | |
| BMR-9762 | BioMarin | Phase 3 | Aβ |